**What is claimed is:**

1. Laquinimod for use in reducing the relapse rate and/or reducing the accumulation of physical disability as assessed by the time to confirmed disease progression in a relapsing-remitting multiple sclerosis human patient, wherein laquinimod is prepared to be administered in a dosage regimen of 0.6 mg laquinimod daily.

2. Laquinimod for use according to claim 1, wherein the time to confirmed disease progression is measured by Kurtzke Expanded Disability Status Scale (EDSS) score.

3. Laquinimod for use according to claims 1 or 2 for reducing the accumulation of physical disability in a patient having an EDSS score of 0-5.5.

4. Laquinimod for use according to claims 1 or 2 for reducing the accumulation of physical disability in a patient having an EDSS score of 5.5 or greater.

5. Laquinimod for use according to claim 3, wherein confirmed disease progression is a 1 point increase of the EDSS score.

6. Laquinimod for use according to claim 4, wherein confirmed disease progression is a 0.5 point increase of the EDSS score.

7. Laquinimod for use according to any one of claims 2-6, wherein time to confirmed disease progression is increased by 20-60%.

8. Laquinimod for use according to any one of claims 1-7, wherein the laquinimod is in the form of laquinimod sodium.

9. Laquinimod for use according to any one of claims 1-8, as a monotherapy for relapsing-remitting multiple sclerosis.

10. Laquinimod for use according to any one of claims 1-8, as an adjunct therapy with an other relapsing-remitting multiple sclerosis treatment.

11. Laquinimod for use according to claim 10, wherein the other relapsing-remitting multiple sclerosis treatment is administration of ~~interferon beta-1a, interferon beta-1b~~ interferon beta 1-a, interferon beta 1-b, glatiramer acetate, mitoxantrone or natalizumab.

12. Laquinimod for use according to any one of claims 1-11, wherein in laquinimod is prepared for daily use for a period of greater than 24 weeks.

13. Laquinimod for use according to claim 12, wherein laquinimod is prepared for daily use for a period of 24 months or more.

14. Laquinimod for use according to any one of claims 1-13, wherein laquinimod is prepared as a pharmaceutical oral unit dosage form comprising of 0.6 mg laquinimod.

24 05 16